Odyssey Therapeutics

ODTX

Biotechnology · Healthcare

Price

$26.39

+1.72 (+6.97%)

Market Cap

$1.27B

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Odyssey Therapeutics is a biotechnology company that discovers and develops new medicines for serious diseases. It focuses on small molecule drugs — pills or compounds that can be taken to treat conditions like inflammatory diseases and cancer. The company is in the early stages of building a drug pipeline, meaning it is working on treatments that have not yet been approved for patients.

Odyssey makes no product revenue yet. It is funded primarily through investor capital and partnerships, which is typical for early-stage biotech companies. The company is based in the United States and operates at a significant loss while it runs research and clinical trials. Its 100% gross margin reflects the absence of product costs, not profitability. The main risk is that drug development is expensive, time-consuming, and often fails — the company must successfully advance its pipeline candidates through clinical trials and secure regulatory approval before it can generate meaningful revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

EPS data limited

R&D Spend

$127M/ year

>1,000% of revenue

236.4x the sector average (18%)

Research and development spending

Insider Activity

15.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~13 months

$176M cash & investments

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial